99 related articles for article (PubMed ID: 69489)
1. Suppression of tumor-specific cell-mediated cytotoxicity by immunoregulatory alpha-globulin and by immunoregulatory alpha-globulin-like peptides from cancer patients.
Wang BS; Badger AM; Nimberg RR; Cooperband SR; Schmid K; Mannick JA
Cancer Res; 1977 Sep; 37(9):3022-5. PubMed ID: 69489
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive activity of IRA on the plaque-forming response to SRBC in vitro: reversal with educated cells.
Badger AM; Merluzzi VJ; Mannick JA; Cooperband SR
J Immunol; 1977 Apr; 118(4):1228-31. PubMed ID: 66281
[TBL] [Abstract][Full Text] [Related]
3. Primary immune response to sheep red blood cells in mice treated with immunoregulatory alpha-globulins (IRA).
Ptak W; Gumińska M; Stachurska B; Czarnik Z
Arch Immunol Ther Exp (Warsz); 1976; 24(5):655-8. PubMed ID: 63274
[TBL] [Abstract][Full Text] [Related]
4. Regulation of T lymphocyte function by immunoregulatory alphaglobulin (IRA).
Menzoian JO; Glasgow AH; Nimberg RD; Cooperband SR; Schmid K; Saporoschetz I; Mannick JA
J Immunol; 1974 Jul; 113(1):266-73. PubMed ID: 4134062
[No Abstract] [Full Text] [Related]
5. Regulation of T-lymphocyte function by immunoregulatory alphaglobulin (IRA).
Menzoian JO; Glasgow A; Cooperband S; Schmid K; Saporoschetz I; Mannick JA
Transplant Proc; 1973 Mar; 5(1):141-3. PubMed ID: 4121168
[No Abstract] [Full Text] [Related]
6. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
Gjedde SB
Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice.
Bekesi JG; Roboz JP; Holland JF
Isr J Med Sci; 1976; 12(4-5):288-303. PubMed ID: 181351
[TBL] [Abstract][Full Text] [Related]
8. In vitro inhibition of cell-mediated cytotoxicity against syngeneic Friend virus-induced leukemia by immunoregulatory alpha globulin.
Glaser M; Ting CC; Herberman RB
J Natl Cancer Inst; 1975 Dec; 55(6):1477-9. PubMed ID: 54438
[TBL] [Abstract][Full Text] [Related]
9. Problems in the use of in vitro assays for monitoring cell-mediated immunity in cancer patients.
de Vries JE
Bull Cancer; 1976; 63(2):279-86. PubMed ID: 791397
[TBL] [Abstract][Full Text] [Related]
10. Immunoregulatory d-globulin: failure to inhibit antibody response when administered after antigen exposure.
Glasgow AH; Menzoian JO; Cooperband SR; Nimberg RB; Schmid K; Mannick JA
J Immunol; 1973 Jul; 111(1):272-4. PubMed ID: 4123372
[No Abstract] [Full Text] [Related]
11. Problems in the clinical use of the microcytotoxicity assay for measuring cell-mediated immunity to tumor cells.
Heppner G; Henry E; Stolbach L; Cummings F; McDonough E; Calabresi P
Cancer Res; 1975 Aug; 35(8):1931-7. PubMed ID: 1149017
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression by spleen cells from Moloney leukemia. Comparison of the suppressive effect on antibody response and on mitogen-induced response.
Cerny J; Stiller RA
J Immunol; 1975 Oct; 115(4):943-9. PubMed ID: 170339
[TBL] [Abstract][Full Text] [Related]
13. Correlation of in vitro and in vivo studies of antigens relevant to the control of murine breast cancer.
Stutman O
Cancer Res; 1976 Feb; 36(2 pt 2):739-47. PubMed ID: 175934
[TBL] [Abstract][Full Text] [Related]
14. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
15. Cell-mediated immune responses to syngeneic ultraviolet-induced tumours. V. Assessment of accessory and antigen-presenting cell capabilities of normal and ultraviolet-irradiated mice in the generation of anti-tumour cytotoxic effector cells in vitro.
Lynch DH; Gurish MF; Daynes RA
Immunology; 1982 Sep; 47(1):49-59. PubMed ID: 6981587
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression of T lymphocyte function by fractionated serum from tumor-bearing mice.
McMaster R; Buhler K; Whitney R; Levy JG
J Immunol; 1977 Jan; 118(1):218-22. PubMed ID: 299757
[TBL] [Abstract][Full Text] [Related]
17. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
Fujii T; Igarashi T; Kishimoto S
J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
[TBL] [Abstract][Full Text] [Related]
18. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
Brunda MJ; Taramelli D; Holden HT; Varesio L
J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
[TBL] [Abstract][Full Text] [Related]
19. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.
Takei F; Levy JG; Kilburn DG
J Immunol; 1976 Feb; 116(2):288-93. PubMed ID: 814160
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.
Ting CC; Rodrigues D
J Natl Cancer Inst; 1982 Oct; 69(4):867-72. PubMed ID: 6214653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
